Data Sheet

Product Name:	Belizatinib
Cat. No.:	CS-6943
CAS No.:	1357920-84-3
Molecular Formula:	C33H44FN5O3
Molecular Weight:	577.73
Target:	ALK; Trk Receptor
Pathway:	Neuronal Signaling; Protein Tyrosine Kinase/RTK
Solubility:	DMSO : ≥ 300 mg/mL (519.27 mM)



BIOLOGICAL ACTIVITY:

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with **IC_{50}** of 0.7 nM for wild-type recombinant ALK kinase. IC50 & Target: IC50: 0.7 nM (ALK)[1] **In Vitro:** TSR-011 has antitumour activity in the clinical trials. **In Vivo:** TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].

References:

[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.

CAIndexNames:

Benzamide, 4-fluoro-N-[6-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-1-[cis-4-[[(1-methylethyl)amino]carbonyl]cyclohexyl]-1H-benzimidazol-2-yl]-

SMILES:

O=C(NC1=NC2=CC=C(CN3CCC(C(C)(O)C)CC3)C=C2N1[C@H]4CC[C@@H](C(NC(C)C)=O)CC4)C5=CC=C(F)C=C5

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA